ARK Invest Seizes Opportunity as CRISPR Therapeutics Stock Dips 10%

CRISPR Therapeutics (CRSP) shares plummeted 10% following the announcement of a $350 million private offering, a move that typically dilutes existing shareholders. Cathie Wood's ARK Invest capitalized on the decline, purchasing approximately 281,000 shares worth $14.82 million across its ETFs. This acquisition reinforces ARK's bullish stance on CRSP, which now stands as its second-largest holding with a 4.49% portfolio weight and $500 million in total exposure.

The private placement, while unsettling short-term investors, aligns with CRISPR Therapeutics' strategic capital needs. ARK's aggressive accumulation of CRSP shares—including a 7.5% position increase in Q4 2025—signals conviction in the biotech firm's long-term potential, despite its current lack of revenue. Meanwhile, ARK trimmed exposure to 10x Genomics (TXG) and Teradyne (TER) as part of routine portfolio rebalancing.

Analyst sentiment remains positive, with both Seeking Alpha Quant and Wall Street maintaining Buy ratings. The market's reaction underscores the tension between near-term dilution concerns and institutional confidence in CRISPR's gene-editing pipeline.